nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—NPY1R—prostate gland—urinary bladder cancer	0.016	0.134	CbGeAlD
Duloxetine—NPY1R—seminal vesicle—urinary bladder cancer	0.0136	0.113	CbGeAlD
Duloxetine—CYP1A2—urine—urinary bladder cancer	0.0117	0.0972	CbGeAlD
Duloxetine—NPY1R—renal system—urinary bladder cancer	0.0109	0.0912	CbGeAlD
Duloxetine—HTR2A—urine—urinary bladder cancer	0.00912	0.076	CbGeAlD
Duloxetine—NPY1R—female reproductive system—urinary bladder cancer	0.00875	0.073	CbGeAlD
Duloxetine—CYP2D6—urine—urinary bladder cancer	0.0083	0.0693	CbGeAlD
Duloxetine—NPY1R—vagina—urinary bladder cancer	0.00792	0.066	CbGeAlD
Duloxetine—NPY1R—lymph node—urinary bladder cancer	0.00512	0.0427	CbGeAlD
Duloxetine—HTR2C—female reproductive system—urinary bladder cancer	0.00356	0.0297	CbGeAlD
Duloxetine—SLC6A4—female reproductive system—urinary bladder cancer	0.00338	0.0282	CbGeAlD
Duloxetine—SLC6A2—female reproductive system—urinary bladder cancer	0.00297	0.0248	CbGeAlD
Duloxetine—CYP1A2—renal system—urinary bladder cancer	0.00285	0.0238	CbGeAlD
Duloxetine—HTR2A—epithelium—urinary bladder cancer	0.0024	0.0201	CbGeAlD
Duloxetine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00232	0.0193	CbGeAlD
Duloxetine—HTR2A—renal system—urinary bladder cancer	0.00223	0.0186	CbGeAlD
Duloxetine—CYP2D6—renal system—urinary bladder cancer	0.00203	0.0169	CbGeAlD
Duloxetine—HTR2A—female reproductive system—urinary bladder cancer	0.00179	0.0149	CbGeAlD
Duloxetine—SLC6A2—lymph node—urinary bladder cancer	0.00174	0.0145	CbGeAlD
Duloxetine—CYP2D6—female reproductive system—urinary bladder cancer	0.00163	0.0136	CbGeAlD
Duloxetine—HTR2A—vagina—urinary bladder cancer	0.00162	0.0135	CbGeAlD
Duloxetine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000434	0.000559	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000433	0.000558	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000432	0.000557	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000431	0.000555	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000429	0.000552	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000428	0.000551	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—urinary bladder cancer	0.000427	0.000549	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000425	0.000547	CcSEcCtD
Duloxetine—Dizziness—Fluorouracil—urinary bladder cancer	0.000425	0.000547	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—urinary bladder cancer	0.000424	0.000546	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000424	0.000545	CcSEcCtD
Duloxetine—Chills—Methotrexate—urinary bladder cancer	0.000422	0.000543	CcSEcCtD
Duloxetine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000416	0.000536	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000416	0.000536	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—urinary bladder cancer	0.000415	0.000535	CcSEcCtD
Duloxetine—Vomiting—Gemcitabine—urinary bladder cancer	0.000415	0.000535	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—urinary bladder cancer	0.000412	0.00053	CcSEcCtD
Duloxetine—Rash—Gemcitabine—urinary bladder cancer	0.000412	0.00053	CcSEcCtD
Duloxetine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000411	0.00053	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—urinary bladder cancer	0.000411	0.000529	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000411	0.000529	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—urinary bladder cancer	0.00041	0.000528	CcSEcCtD
Duloxetine—Erythema—Methotrexate—urinary bladder cancer	0.000409	0.000527	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—urinary bladder cancer	0.000409	0.000527	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000409	0.000527	CcSEcCtD
Duloxetine—Headache—Gemcitabine—urinary bladder cancer	0.000409	0.000527	CcSEcCtD
Duloxetine—Flushing—Epirubicin—urinary bladder cancer	0.000408	0.000526	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000408	0.000526	CcSEcCtD
Duloxetine—Vomiting—Fluorouracil—urinary bladder cancer	0.000408	0.000526	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000407	0.000524	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000407	0.000524	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000405	0.000521	CcSEcCtD
Duloxetine—Rash—Fluorouracil—urinary bladder cancer	0.000405	0.000521	CcSEcCtD
Duloxetine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000404	0.000521	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000404	0.00052	CcSEcCtD
Duloxetine—Headache—Fluorouracil—urinary bladder cancer	0.000402	0.000518	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000402	0.000518	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000401	0.000516	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000401	0.000516	CcSEcCtD
Duloxetine—Asthenia—Etoposide—urinary bladder cancer	0.0004	0.000515	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.0004	0.000515	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—urinary bladder cancer	0.000399	0.000514	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000399	0.000514	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000397	0.000512	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000397	0.00051	CcSEcCtD
Duloxetine—Back pain—Methotrexate—urinary bladder cancer	0.000396	0.00051	CcSEcCtD
Duloxetine—Chills—Epirubicin—urinary bladder cancer	0.000395	0.000508	CcSEcCtD
Duloxetine—Pruritus—Etoposide—urinary bladder cancer	0.000395	0.000508	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000393	0.000506	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000392	0.000505	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—urinary bladder cancer	0.000389	0.0005	CcSEcCtD
Duloxetine—Nausea—Gemcitabine—urinary bladder cancer	0.000388	0.000499	CcSEcCtD
Duloxetine—Vomiting—Cisplatin—urinary bladder cancer	0.000387	0.000498	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—urinary bladder cancer	0.000386	0.000497	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—urinary bladder cancer	0.000385	0.000496	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000385	0.000496	CcSEcCtD
Duloxetine—Rash—Cisplatin—urinary bladder cancer	0.000384	0.000494	CcSEcCtD
Duloxetine—Dermatitis—Cisplatin—urinary bladder cancer	0.000383	0.000494	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—urinary bladder cancer	0.000383	0.000493	CcSEcCtD
Duloxetine—Erythema—Epirubicin—urinary bladder cancer	0.000383	0.000493	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—urinary bladder cancer	0.000382	0.000491	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—urinary bladder cancer	0.000381	0.000491	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00038	0.00049	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00038	0.000489	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00038	0.000489	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—urinary bladder cancer	0.000378	0.000487	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—urinary bladder cancer	0.000378	0.000486	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000378	0.000486	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—urinary bladder cancer	0.000377	0.000486	CcSEcCtD
Duloxetine—Tension—Epirubicin—urinary bladder cancer	0.000376	0.000484	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000375	0.000483	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—urinary bladder cancer	0.000372	0.000479	CcSEcCtD
Duloxetine—Back pain—Epirubicin—urinary bladder cancer	0.00037	0.000477	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000369	0.000475	CcSEcCtD
Duloxetine—Malaise—Methotrexate—urinary bladder cancer	0.000369	0.000475	CcSEcCtD
Duloxetine—Dizziness—Etoposide—urinary bladder cancer	0.000369	0.000475	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000368	0.000474	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000368	0.000473	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—urinary bladder cancer	0.000368	0.000473	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000367	0.000472	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—urinary bladder cancer	0.000366	0.000472	CcSEcCtD
Duloxetine—Chills—Doxorubicin—urinary bladder cancer	0.000365	0.00047	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000364	0.000468	CcSEcCtD
Duloxetine—Nausea—Cisplatin—urinary bladder cancer	0.000362	0.000465	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—urinary bladder cancer	0.000361	0.000465	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—urinary bladder cancer	0.00036	0.000463	CcSEcCtD
Duloxetine—Cough—Methotrexate—urinary bladder cancer	0.000357	0.00046	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000357	0.000459	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000355	0.000457	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—urinary bladder cancer	0.000355	0.000456	CcSEcCtD
Duloxetine—Vomiting—Etoposide—urinary bladder cancer	0.000355	0.000456	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000354	0.000456	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—urinary bladder cancer	0.000354	0.000456	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—urinary bladder cancer	0.000354	0.000456	CcSEcCtD
Duloxetine—Agitation—Epirubicin—urinary bladder cancer	0.000352	0.000453	CcSEcCtD
Duloxetine—Rash—Etoposide—urinary bladder cancer	0.000352	0.000453	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—urinary bladder cancer	0.000351	0.000452	CcSEcCtD
Duloxetine—Headache—Etoposide—urinary bladder cancer	0.000349	0.00045	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—urinary bladder cancer	0.000349	0.00045	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—urinary bladder cancer	0.000348	0.000449	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—urinary bladder cancer	0.000348	0.000449	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—urinary bladder cancer	0.000348	0.000449	CcSEcCtD
Duloxetine—Tension—Doxorubicin—urinary bladder cancer	0.000348	0.000448	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000347	0.000447	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000346	0.000445	CcSEcCtD
Duloxetine—Malaise—Epirubicin—urinary bladder cancer	0.000345	0.000445	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—urinary bladder cancer	0.000344	0.000443	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—urinary bladder cancer	0.000344	0.000443	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—urinary bladder cancer	0.000344	0.000443	CcSEcCtD
Duloxetine—Syncope—Epirubicin—urinary bladder cancer	0.000343	0.000442	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—urinary bladder cancer	0.000343	0.000441	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—urinary bladder cancer	0.000343	0.000441	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000341	0.000439	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—urinary bladder cancer	0.000338	0.000436	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—urinary bladder cancer	0.000337	0.000434	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000337	0.000433	CcSEcCtD
Duloxetine—Cough—Epirubicin—urinary bladder cancer	0.000334	0.00043	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000334	0.00043	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000334	0.00043	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—urinary bladder cancer	0.000332	0.000427	CcSEcCtD
Duloxetine—Infection—Methotrexate—urinary bladder cancer	0.000332	0.000427	CcSEcCtD
Duloxetine—Nausea—Etoposide—urinary bladder cancer	0.000331	0.000426	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—urinary bladder cancer	0.000331	0.000426	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000329	0.000423	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000328	0.000422	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—urinary bladder cancer	0.000328	0.000422	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000327	0.000421	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—urinary bladder cancer	0.000326	0.00042	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—urinary bladder cancer	0.000326	0.00042	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—urinary bladder cancer	0.000326	0.00042	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—urinary bladder cancer	0.000326	0.000419	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—urinary bladder cancer	0.000325	0.000418	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—urinary bladder cancer	0.000324	0.000418	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000324	0.000417	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000323	0.000416	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—urinary bladder cancer	0.000322	0.000415	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—urinary bladder cancer	0.00032	0.000411	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—urinary bladder cancer	0.000319	0.000411	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—urinary bladder cancer	0.000318	0.00041	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—urinary bladder cancer	0.000318	0.00041	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—urinary bladder cancer	0.000318	0.000409	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000317	0.000408	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—urinary bladder cancer	0.000315	0.000406	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—urinary bladder cancer	0.000313	0.000403	CcSEcCtD
Duloxetine—Oedema—Epirubicin—urinary bladder cancer	0.000313	0.000402	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000313	0.000402	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000311	0.000401	CcSEcCtD
Duloxetine—Infection—Epirubicin—urinary bladder cancer	0.000311	0.0004	CcSEcCtD
Duloxetine—Cough—Doxorubicin—urinary bladder cancer	0.000309	0.000398	CcSEcCtD
Duloxetine—Shock—Epirubicin—urinary bladder cancer	0.000308	0.000396	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—urinary bladder cancer	0.000307	0.000395	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000307	0.000395	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000306	0.000394	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—urinary bladder cancer	0.000306	0.000394	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—urinary bladder cancer	0.000305	0.000393	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000304	0.000392	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—urinary bladder cancer	0.000304	0.000391	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000302	0.000389	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—urinary bladder cancer	0.000302	0.000389	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000302	0.000388	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—urinary bladder cancer	0.000302	0.000388	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—urinary bladder cancer	0.000302	0.000388	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—urinary bladder cancer	0.000301	0.000387	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—urinary bladder cancer	0.0003	0.000386	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.0003	0.000386	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—urinary bladder cancer	0.000298	0.000384	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—urinary bladder cancer	0.000298	0.000384	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—urinary bladder cancer	0.000297	0.000382	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000295	0.00038	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000294	0.000378	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—urinary bladder cancer	0.000292	0.000375	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—urinary bladder cancer	0.00029	0.000374	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000289	0.000372	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—urinary bladder cancer	0.000289	0.000372	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000288	0.000371	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—urinary bladder cancer	0.000288	0.000371	CcSEcCtD
Duloxetine—Infection—Doxorubicin—urinary bladder cancer	0.000287	0.00037	CcSEcCtD
Duloxetine—Pain—Methotrexate—urinary bladder cancer	0.000286	0.000368	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000285	0.000367	CcSEcCtD
Duloxetine—Shock—Doxorubicin—urinary bladder cancer	0.000285	0.000366	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000284	0.000365	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000283	0.000365	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—urinary bladder cancer	0.000283	0.000364	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000282	0.000363	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000281	0.000362	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000281	0.000361	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00028	0.00036	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—urinary bladder cancer	0.000278	0.000358	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—urinary bladder cancer	0.000276	0.000355	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000275	0.000354	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000275	0.000354	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000273	0.000352	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000272	0.00035	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00027	0.000347	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—urinary bladder cancer	0.000269	0.000347	CcSEcCtD
Duloxetine—Constipation—Epirubicin—urinary bladder cancer	0.000267	0.000344	CcSEcCtD
Duloxetine—Pain—Epirubicin—urinary bladder cancer	0.000267	0.000344	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—urinary bladder cancer	0.000265	0.000342	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000264	0.00034	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000264	0.00034	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000264	0.000339	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—urinary bladder cancer	0.000262	0.000337	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00026	0.000334	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000258	0.000332	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—urinary bladder cancer	0.000257	0.000331	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000256	0.000329	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000255	0.000328	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000251	0.000324	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00025	0.000321	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—urinary bladder cancer	0.000249	0.000321	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—urinary bladder cancer	0.000248	0.00032	CcSEcCtD
Duloxetine—Pain—Doxorubicin—urinary bladder cancer	0.000247	0.000318	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—urinary bladder cancer	0.000247	0.000318	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000247	0.000318	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000247	0.000318	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000246	0.000317	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—urinary bladder cancer	0.00024	0.000309	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000238	0.000307	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000237	0.000304	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—urinary bladder cancer	0.000236	0.000304	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00023	0.000296	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—urinary bladder cancer	0.00023	0.000296	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000229	0.000294	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000229	0.000294	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000229	0.000294	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—urinary bladder cancer	0.000224	0.000289	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—urinary bladder cancer	0.000221	0.000285	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—urinary bladder cancer	0.000221	0.000284	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000214	0.000275	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000213	0.000274	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—urinary bladder cancer	0.000212	0.000273	CcSEcCtD
Duloxetine—Rash—Methotrexate—urinary bladder cancer	0.000211	0.000271	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—urinary bladder cancer	0.00021	0.000271	CcSEcCtD
Duloxetine—Headache—Methotrexate—urinary bladder cancer	0.000209	0.000269	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—urinary bladder cancer	0.000208	0.000267	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—urinary bladder cancer	0.000207	0.000266	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—urinary bladder cancer	0.000205	0.000263	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—urinary bladder cancer	0.000199	0.000256	CcSEcCtD
Duloxetine—Nausea—Methotrexate—urinary bladder cancer	0.000198	0.000255	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000198	0.000255	CcSEcCtD
Duloxetine—Rash—Epirubicin—urinary bladder cancer	0.000197	0.000254	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—urinary bladder cancer	0.000197	0.000253	CcSEcCtD
Duloxetine—Headache—Epirubicin—urinary bladder cancer	0.000196	0.000252	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—urinary bladder cancer	0.000191	0.000246	CcSEcCtD
Duloxetine—Nausea—Epirubicin—urinary bladder cancer	0.000186	0.000239	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—urinary bladder cancer	0.000184	0.000237	CcSEcCtD
Duloxetine—Rash—Doxorubicin—urinary bladder cancer	0.000182	0.000235	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000182	0.000235	CcSEcCtD
Duloxetine—Headache—Doxorubicin—urinary bladder cancer	0.000181	0.000233	CcSEcCtD
Duloxetine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.00018	0.00174	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000174	0.00169	CbGpPWpGaD
Duloxetine—Nausea—Doxorubicin—urinary bladder cancer	0.000172	0.000221	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000169	0.00164	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000168	0.00163	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000166	0.00161	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000164	0.00159	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000159	0.00154	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000157	0.00152	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000155	0.0015	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	0.000152	0.00147	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000151	0.00146	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00015	0.00145	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000149	0.00145	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000149	0.00145	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—S100B—urinary bladder cancer	0.000149	0.00144	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000145	0.00141	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000145	0.00141	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000142	0.00138	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—RHOA—urinary bladder cancer	0.000141	0.00137	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000141	0.00136	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000136	0.00132	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NCOR1—urinary bladder cancer	0.000134	0.0013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HDAC4—urinary bladder cancer	0.000132	0.00128	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000131	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000131	0.00126	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—urinary bladder cancer	0.00013	0.00126	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.00013	0.00126	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00013	0.00125	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000129	0.00125	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000127	0.00123	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000127	0.00123	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000124	0.0012	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000121	0.00117	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000121	0.00117	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000121	0.00117	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.00012	0.00116	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000119	0.00115	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—urinary bladder cancer	0.000118	0.00115	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TERT—urinary bladder cancer	0.000118	0.00114	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000117	0.00113	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000112	0.00108	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000111	0.00107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GLI1—urinary bladder cancer	0.000111	0.00107	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000109	0.00106	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	0.000109	0.00105	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—FGFR3—urinary bladder cancer	0.000108	0.00105	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ESR1—urinary bladder cancer	0.000105	0.00102	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000102	0.00099	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HDAC4—urinary bladder cancer	9.72e-05	0.000941	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CREBBP—urinary bladder cancer	9.22e-05	0.000892	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—urinary bladder cancer	9.1e-05	0.000881	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	9.09e-05	0.00088	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—urinary bladder cancer	9.06e-05	0.000877	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL8—urinary bladder cancer	8.91e-05	0.000862	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.73e-05	0.000845	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	8.61e-05	0.000834	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—KRAS—urinary bladder cancer	8.56e-05	0.000828	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	8.5e-05	0.000823	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HDAC4—urinary bladder cancer	8.44e-05	0.000817	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RHOA—urinary bladder cancer	8.34e-05	0.000807	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.27e-05	0.000801	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.27e-05	0.000801	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLI1—urinary bladder cancer	8.14e-05	0.000788	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	8.03e-05	0.000778	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.95e-05	0.00077	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.93e-05	0.000768	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB2—urinary bladder cancer	7.72e-05	0.000747	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RBX1—urinary bladder cancer	7.58e-05	0.000734	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.57e-05	0.000733	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.48e-05	0.000724	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	7.39e-05	0.000716	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	7.38e-05	0.000715	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL8—urinary bladder cancer	7.32e-05	0.000709	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRAS—urinary bladder cancer	7.27e-05	0.000704	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSC1—urinary bladder cancer	7.13e-05	0.00069	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLI1—urinary bladder cancer	7.07e-05	0.000685	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.03e-05	0.00068	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	7.01e-05	0.000679	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	7.01e-05	0.000679	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—urinary bladder cancer	7e-05	0.000677	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	6.97e-05	0.000675	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.89e-05	0.000667	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	6.83e-05	0.000661	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—urinary bladder cancer	6.82e-05	0.00066	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.81e-05	0.00066	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JAG1—urinary bladder cancer	6.78e-05	0.000657	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—urinary bladder cancer	6.62e-05	0.000641	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN1A—urinary bladder cancer	6.6e-05	0.000639	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—urinary bladder cancer	6.58e-05	0.000637	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—urinary bladder cancer	6.56e-05	0.000635	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.43e-05	0.000623	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	6.41e-05	0.000621	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EP300—urinary bladder cancer	6.28e-05	0.000608	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.27e-05	0.000607	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SRC—urinary bladder cancer	6.1e-05	0.000591	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	6.09e-05	0.00059	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	5.93e-05	0.000574	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	5.77e-05	0.000559	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—RHOA—urinary bladder cancer	5.73e-05	0.000555	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—urinary bladder cancer	5.7e-05	0.000551	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RBX1—urinary bladder cancer	5.58e-05	0.00054	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—S100B—urinary bladder cancer	5.49e-05	0.000532	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—urinary bladder cancer	5.47e-05	0.00053	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	5.45e-05	0.000528	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—urinary bladder cancer	5.35e-05	0.000518	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	5.31e-05	0.000514	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC1—urinary bladder cancer	5.25e-05	0.000508	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RHOA—urinary bladder cancer	5.21e-05	0.000504	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—urinary bladder cancer	5.05e-05	0.000489	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.03e-05	0.000487	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.01e-05	0.000485	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAG1—urinary bladder cancer	5e-05	0.000484	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NCOR1—urinary bladder cancer	4.94e-05	0.000478	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RBX1—urinary bladder cancer	4.85e-05	0.000469	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—urinary bladder cancer	4.81e-05	0.000466	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—urinary bladder cancer	4.57e-05	0.000443	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC1—urinary bladder cancer	4.56e-05	0.000441	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.53e-05	0.000439	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—urinary bladder cancer	4.49e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—urinary bladder cancer	4.37e-05	0.000423	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—urinary bladder cancer	4.35e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAG1—urinary bladder cancer	4.34e-05	0.00042	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—urinary bladder cancer	4.3e-05	0.000416	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.26e-05	0.000412	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	4.25e-05	0.000411	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—RHOA—urinary bladder cancer	4.22e-05	0.000409	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.08e-05	0.000395	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	4.04e-05	0.000392	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGFR3—urinary bladder cancer	3.99e-05	0.000387	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.91e-05	0.000379	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—urinary bladder cancer	3.88e-05	0.000376	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.84e-05	0.000372	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	3.83e-05	0.000371	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.71e-05	0.000359	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RHOA—urinary bladder cancer	3.67e-05	0.000355	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	3.64e-05	0.000352	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.62e-05	0.000351	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.62e-05	0.000351	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	3.54e-05	0.000343	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.52e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—urinary bladder cancer	3.51e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREBBP—urinary bladder cancer	3.4e-05	0.000329	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	3.37e-05	0.000326	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—urinary bladder cancer	3.36e-05	0.000325	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—urinary bladder cancer	3.34e-05	0.000323	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	3.33e-05	0.000322	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.32e-05	0.000321	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.22e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	3.22e-05	0.000311	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	3.21e-05	0.00031	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.16e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—urinary bladder cancer	3.16e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.08e-05	0.000298	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RHOA—urinary bladder cancer	3.08e-05	0.000298	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.07e-05	0.000297	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.07e-05	0.000297	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.05e-05	0.000296	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.98e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	2.94e-05	0.000285	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.93e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.92e-05	0.000283	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.92e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	2.86e-05	0.000277	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—urinary bladder cancer	2.85e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	2.79e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	2.78e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—urinary bladder cancer	2.7e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—urinary bladder cancer	2.68e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—urinary bladder cancer	2.58e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.55e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—urinary bladder cancer	2.52e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	2.5e-05	0.000242	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	2.48e-05	0.00024	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.47e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	2.47e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	2.46e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—urinary bladder cancer	2.44e-05	0.000236	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.44e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—urinary bladder cancer	2.43e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—urinary bladder cancer	2.43e-05	0.000235	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.4e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	2.32e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—urinary bladder cancer	2.32e-05	0.000224	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.27e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	2.27e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—urinary bladder cancer	2.25e-05	0.000218	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.24e-05	0.000217	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.24e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.17e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	2.15e-05	0.000208	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.14e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.14e-05	0.000207	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.11e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	2.1e-05	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.09e-05	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.06e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.02e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	2.02e-05	0.000195	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.99e-05	0.000193	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.98e-05	0.000192	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.98e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	1.97e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.97e-05	0.00019	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.92e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.9e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.9e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.9e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.86e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.85e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.82e-05	0.000176	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.82e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.8e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.79e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.79e-05	0.000173	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.78e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.73e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.72e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.71e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.68e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.66e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.66e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.65e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.61e-05	0.000156	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.6e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.58e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.56e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.56e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.55e-05	0.00015	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.54e-05	0.000149	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.49e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.48e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.45e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.44e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.37e-05	0.000133	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.36e-05	0.000132	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.31e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.29e-05	0.000125	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.22e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.19e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.17e-05	0.000113	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.1e-05	0.000107	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	1.06e-05	0.000103	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.05e-05	0.000102	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	1.01e-05	9.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	9.33e-06	9.03e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—urinary bladder cancer	8.89e-06	8.61e-05	CbGpPWpGaD
